Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a stock that investors should take a bite out of.

After closing at $113.90 in the most recent trading day, Sarepta Therapeutics Inc. (NASDAQ: SRPT) closed at 110.14, down -3.30%. In other words, the price has decreased by $-3.76 from its previous closing price. On the day, 1022020 shares were traded. SRPT reached its highest trading level at $115.40 during the session, while it also had its lowest trading level at $110.07.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.52.

Upgrades & Downgrades

On January 05, 2022, Needham reiterated its Buy rating and also upped its target price recommendation from $157 to $150.

Oppenheimer Upgraded its Perform to Outperform on December 09, 2021, while the target price for the stock was maintained at $125.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 14 when Chambers Michael Andrew bought 57,100 shares for $104.43 per share. The transaction valued at 5,963,124 led to the insider holds 108,178 shares of the business.

Chambers Michael Andrew bought 46,170 shares of SRPT for $4,999,230 on Aug 19. The Director now owns 51,078 shares after completing the transaction at $108.28 per share. On Nov 24, another insider, Rodino-Klapac Louise, who serves as the Head of R&D, CSO of the company, bought 3,780 shares for $79.33 each. As a result, the insider paid 299,867 and bolstered with 65,678 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 11.41 while its Price-to-Book (P/B) ratio in mrq is 13.27.

Stock Price History:

Over the past 52 weeks, SRPT has reached a high of $120.23, while it has fallen to a 52-week low of $61.28. The 50-Day Moving Average of the stock is 102.19, while the 200-Day Moving Average is calculated to be 83.18.

Shares Statistics:

The stock has traded on average 1.12M shares per day over the past 3-months and 1.73M shares per day over the last 10 days, according to various share statistics. A total of 87.51M shares are outstanding, with a floating share count of 83.78M. Insiders hold about 0.10% of the company’s shares, while institutions hold 83.60% stake in the company. Shares short for SRPT as of Jul 14, 2022 were 5.36M with a Short Ratio of 5.85, compared to 4.98M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.13% and a Short% of Float of 6.41%.

Earnings Estimates

Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of $-1.18 for the current quarter, with a high estimate of $-0.88 and a low estimate of $-1.7, while EPS last year was $-1.02. The consensus estimate for the next quarter is $-1.07, with high estimates of $-0.43 and low estimates of $-1.65.

Analysts are recommending an EPS of between $-3.55 and $-6.1 for the fiscal current year, implying an average EPS of $-4.63. EPS for the following year is $-3.54, with 15 analysts recommending between $-1.08 and $-6.42.

Revenue Estimates

A total of 18 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $919.43M, while the lowest revenue estimate was $882.2M, resulting in an average revenue estimate of $899.91M. In the same quarter a year ago, actual revenue was $701.89M, up 28.20% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $1.06B in the next fiscal year. The high estimate is $1.27B and the low estimate is $928M. The average revenue growth estimate for next year is up 17.20% from the average revenue estimate for this year.